Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow
Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...
The Secret Excel Function That Simplifies Data Like Never Before
Learn how to master Excel's MOD function for smarter data management, advanced analysis, and streamlined workflows in your ...
Power Engineering16h
AI’s power play: Meeting the growing energy demands of data centers
AI and data centers are reshaping the energy landscape and market participants are scrambling to meet skyrocketing power ...
Exelixis targets $5B Zanza sales by 2033 with multiple pivotal trials in progress
CEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the company's goal of achieving $3 billion in annual cabozantinib (Cabo) revenue by 2030 and $5 billion for zanzalintinib ...